Lexicon Pharmaceuticals, Inc. reports developments as a Nasdaq-listed biopharmaceutical company focused on the discovery, development and commercialization of medicines for human disease. Company news commonly covers pipeline updates in neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders and other cardiometabolic indications, including clinical data presentations for sotagliflozin and pilavapadin.
Recurring updates also include operating and financial results, regulatory interactions, material agreements, financing arrangements and governance or shareholder-voting matters. Coverage of LXRX often connects capital-structure actions with the resources used to advance clinical and preclinical drug candidates.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that CEO Lonnel Coats will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 10:30 a.m. ET. The presentation will be accessible via a live webcast on the company's website, with an archived version available for two weeks post-event. Lexicon is focused on developing innovative medicines, leveraging its Genome5000™ program to identify therapeutic protein targets across various diseases, including neuropathic pain and diabetes.
Lexicon Pharmaceuticals (Nasdaq: LXRX) has submitted a New Drug Application (NDA) to the FDA for sotagliflozin, aimed at reducing the risk of cardiovascular death and hospitalization in adults with type 2 diabetes and heart failure. Supported by findings from the Phase 3 SOLOIST and SCORED studies, the NDA submission marks a significant step towards potential market approval. Both clinical trials achieved their primary endpoints, indicating that sotagliflozin could offer essential benefits to patients suffering from these conditions.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced its virtual participation in two upcoming healthcare conferences. The Jefferies London Healthcare Conference will occur from November 16-19, 2021, with CEO Lonnel Coats presenting on-demand starting November 18 at 3:00 am ET. The Piper Sandler 33rd Annual Healthcare Conference will take place from November 30 to December 2, 2021, featuring a fireside chat with executive management available on-demand starting November 22 at 10:00 am ET. Recordings will be accessible on Lexicon's website for two weeks post-event.
Lexicon Pharmaceuticals (Nasdaq: LXRX) presented a post hoc analysis of clinical data from the SOLOIST and SCORED trials at the American Heart Association Scientific Sessions 2021. The analysis revealed that sotagliflozin significantly reduced total cardiovascular deaths, heart failure hospitalizations, and urgent heart failure visits across various kidney function levels. Additionally, it lowered hemoglobin A1c in patients, including those with chronic kidney disease. The data supports a new drug application to the FDA planned for year-end, indicating potential for sotagliflozin as a key therapeutic option in heart failure associated with type 2 diabetes.
Lexicon Pharmaceuticals (Nasdaq: LXRX) announced a new analysis of sotagliflozin results from the SOLOIST and SCORED Phase 3 studies will be presented at the virtual American Heart Association Scientific Sessions on November 14. Dr. Deepak L. Bhatt will present findings on the cardiovascular benefits of sotagliflozin across varying kidney functions. Both studies previously achieved their primary endpoints, showing significant cardiovascular efficacy in patients with type 2 diabetes and heart failure. The newly analyzed data will be made available during the presentation.
Lexicon Pharmaceuticals (Nasdaq: LXRX) reported its Q3 2021 financial results, showing negligible revenues compared to $6.6 million in Q3 2020, primarily due to the sale of XERMELO. R&D expenses decreased to $15.7 million from $40.1 million, while SG&A expenses fell to $7.3 million from $12 million. The net loss for Q3 2021 was $23.1 million, or $0.16 per share, contrasted with a net income of $82.6 million in the same quarter last year, which included a significant gain from the asset sale. Lexicon aims to submit a new drug application for sotagliflozin by year-end.
Lexicon Pharmaceuticals (LXRX) will announce its Q3 2021 financial results on November 3, 2021, after market close. A conference call will follow at 5:00 p.m. ET to discuss these results and provide a business update. The call can be accessed via U.S. and international dial-in numbers. Lexicon focuses on pioneering medicines with a strong pipeline including drug candidates for neuropathic pain and diabetes. Forward-looking statements regarding the company’s financial health and drug development trajectory have been made but come with inherent risks.
On September 15, 2021, Lexicon Pharmaceuticals (Nasdaq: LXRX) announced that President and CEO Lonnel Coats will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. The presentation is scheduled for September 21, 2021, at 10:45 a.m. ET. A webcast of the event will be made available on Lexicon’s website, with an archived version accessible for two weeks following the event.
Lexicon is dedicated to pioneering medicines that transform patients' lives, focusing on therapeutic targets identified through its Genome5000™ program.
Lexicon Pharmaceuticals (Nasdaq: LXRX) supports the European Society of Cardiology's updated guidelines recommending SGLT inhibitors for heart failure treatment. This recommendation emphasizes the drugs' Class IA endorsement for reducing cardiovascular death and hospitalization risks in patients, especially those with diabetes. Notably, sotagliflozin, an investigational drug, was highlighted for its potential benefits before regulatory approval. Lexicon plans to file a New Drug Application with the FDA later this year for sotagliflozin as a heart failure therapy.
Lexicon Pharmaceuticals (LXRX) announced findings from the SOLOIST and SCORED trials for sotagliflozin at ESC Congress 2021. The trials revealed a 33% absolute reduction in cardiovascular risks for type 2 diabetes patients with acute heart failure and a 26% reduction in those with chronic kidney disease. Notably, the 400 mg dosage showed significant benefits in reducing heart failure events. The company plans to submit a New Drug Application for sotagliflozin, highlighting its potential as a treatment for heart failure in diabetes patients.